Extends support for ALS research and improves how new therapies are studied and reported.
This bill would extend a law that supports research into treatments for ALS, also known as Lou Gehrig's disease, through 2031. It would also improve government review of grants for new ALS therapies and require more detailed reports from the Food and Drug Administration on rare neurodegenerative diseases.
Today, the Accelerating Access to Critical Therapies for ALS Act and its research grants are authorized through the government's budget year 2026. The FDA publishes an initial action plan for rare brain and nerve diseases. If this bill becomes law, the Act and its grants would continue through 2031, ensuring ongoing support for ALS research. Grant recipients would face new requirements for reporting safety data, and the FDA would need to update its action plans every five years with more detailed information.
S 4472 · 119th Congress · April 30, 2026 · AI Summary by gemini-2.5-flash · 9/10
Sign in to see your representatives' phone numbers